While the specific mechanisms of IFN-mediated tumor rejection in animal models have not been fully elucidated, IFN-α has been the most widely investigated cytokine for human cancer treatment and may prove to be a valuable component of combinatorial strategies for immunotherapy of solid tumors. This evidence concerns the gene IFNA1 and neoplasm.